Gunther Birznieks Biography and Net Worth

SVP of Vanda Pharmaceuticals

Gunther Birznieks is Vanda's Senior Vice President, Business Development and member of the R&D Committee. Prior to his current role, Gunther Birznieks held a number of positions at Vanda Pharmaceuticals including as Clinical Program Head of the Hetlioz and VSF-173 programs, Head of Informatics and in Singapore as Head of Operations since 2003. Mr. Birznieks previously spent the majority of his career in the areas of healthcare and biomedical informatics including bioinformatics support for microarray and genotyping projects with the Human Genome Project at NHGRI. Prior to joining to Vanda, Gunther Birznieks founded Extropia Pte Ltd, a Singaporean company which specialized in business and investment banking applications. Gunther Birznieks has published four books on computer technologies as well as numerous articles and talks on information security, programming, and software development life cycle. He holds a B. A. in Psychology and M. S. in Computer Science from Johns Hopkins University.

What is Gunther Birznieks' net worth?: The estimated net worth of Gunther Birznieks is at least $3.41 million as of March 2nd, 2026. Mr. Birznieks owns 494,197 shares of Vanda Pharmaceuticals stock worth more than $3,405,017 as of April 27th. This net worth evaluation does not reflect any other assets that Mr. Birznieks may own. Learn More about Gunther Birznieks' net worth.
How do I contact Gunther Birznieks?: The corporate mailing address for Mr. Birznieks and other Vanda Pharmaceuticals executives is 2200 PENNSYLVANIA AVENUE NW SUITE 300 E, WASHINGTON DC, 20037. Vanda Pharmaceuticals can also be reached via phone at (202) 734-3400 and via email at [email protected]. Learn More on Gunther Birznieks' contact information.
Has Gunther Birznieks been buying or selling shares of Vanda Pharmaceuticals?: Gunther Birznieks has not been actively trading shares of Vanda Pharmaceuticals during the last ninety days. Most recently, Gunther Birznieks sold 42,431 shares of the business's stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $8.27, for a transaction totalling $350,904.37. Following the completion of the sale, the senior vice president now directly owns 494,197 shares of the company's stock, valued at $4,087,009.19. Learn More on Gunther Birznieks' trading history.
Who are Vanda Pharmaceuticals' active insiders?: Vanda Pharmaceuticals' insider roster includes Gunther Birznieks (SVP), Phaedra Chrousos (Director), Aranthan Jones, II (Insider), Stephen Mitchell (Director), Kevin Moran (CFO), Mihael Polymeropoulos (CEO), Joakim Wijkstrom (CMO), and Timothy Williams (SVP). Learn More on Vanda Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Vanda Pharmaceuticals?: In the last twelve months, Vanda Pharmaceuticals insiders bought shares 2 times. They purchased a total of 30,000 shares worth more than $128,400.00. In the last twelve months, insiders at the biopharmaceutical company sold shares 6 times. They sold a total of 321,342 shares worth more than $2,616,114.84. The most recent insider tranaction occured on March, 2nd when SVP Timothy Williams sold 42,434 shares worth more than $350,929.18. Insiders at Vanda Pharmaceuticals own 8.9% of the company. Learn More about insider trades at Vanda Pharmaceuticals.
Information on this page was last updated on 3/2/2026.

Gunther Birznieks Insider Trading History at Vanda Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/2/2026	Sell	42,431	$8.27	$350,904.37	494,197
3/2/2021	Sell	20,465	$18.28	$374,100.20
3/1/2018	Sell	8,525	$18.72	$159,588.00	148,366
1/2/2018	Sell	8,568	$15.26	$130,747.68	118,366

Gunther Birznieks Buying and Selling Activity at Vanda Pharmaceuticals

Vanda Pharmaceuticals Company Overview

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Today's Range

Now: $7.08

$6.88

$7.18

50 Day Range

MA: $7.52

$5.76

$9.56

2 Week Range

Now: $7.08

$3.81

$9.94

Volume

435,166 shs

Average Volume

2,285,704 shs

Market Capitalization

$425.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.71